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Key messages
 ► What is the extent of telehealth use in chronic ob-
structive pulmonary disease (COPD) across National 
Health Service England and Wales, and which tech-
niques are used by healthcare providers when set-
ting telehealth alarm limits?
 ► Around one-third of COPD services who responded 
to our survey were using telehealth, believing it to 
be effective despite the absence of robust evidence, 
and using a variety of methods to personalise tele-
health alarm limits.
 ► This is the first study to report on methods used to 
specify telehealth alarm limits in patients with COPD 
across England and Wales, and to examine for what 
purposes the service was provided.
AbstrAct
Introduction Although the effectiveness of domiciliary 
monitoring (telehealth) to improve outcomes in chronic 
obstructive pulmonary disease (COPD) is controversial, it is 
being used in the National Health Service (NHS).
Aim To explore the use of teleheath for COPD across 
England and Wales, to assess the perceptions of clinicians 
employing telehealth in COPD and to summarise the 
techniques that have been used by healthcare providers to 
personalise alarm limits for patients with COPD enrolled in 
telehealth programmes.
Methods A cross-sectional survey consisting of 14 
questions was sent to 230 COPD community services in 
England and Wales. Questions were designed to cover five 
aspects of telehealth in COPD: purpose of use, equipment 
type, clinician perceptions, variables monitored and 
personalisation of alarm limits.
results 65 participants completed the survey from 52 
different NHS Trusts. 46% of Trusts had used telehealth for 
COPD, and currently, 31% still provided telehealth services 
to patients with COPD. Telehealth is most commonly used 
for baseline monitoring and to allow early detection of 
exacerbations, with 54% believing it to be effective. The 
three most commonly monitored variables were oxygen 
saturation, heart rate and breathlessness. A variety of 
methods were used to set alarm limits with the majority 
of respondents believing that at least 40% of alarms were 
false.
conclusion Around one-third of responded community 
COPD services are using telehealth, believing it to be 
effective without robust evidence, with a variety of 
variables monitored, a variety of hardware and varying 
techniques to set alarm limits with high false alarm 
frequencies.
IntroductIon
Chronic obstructive pulmonary disease 
(COPD) imposes a global burden on individ-
uals and healthcare systems. COPD is defined 
as ‘a common, preventable and treatable disease that 
is characterized by persistent respiratory symptoms 
and airflow limitation that due to airway and/or 
alveolar abnormalities usually caused by significant 
exposure to noxious particles or gases.’1 According 
to the British Lung Foundation, 1.2 million 
individuals are diagnosed with COPD in the 
UK and there are many more undiagnosed—
the ‘missing millions’.2 3 Snell et al reported 
that 29 776 patients died because of COPD in 
2012, which makes it the fifth leading cause 
of death in the UK.2 3 The annual direct cost 
of COPD is reported to be nearly £1 billion 
with more than 1 million bed-days, and 140 
000 hospital admissions annually.2 Much of 
the morbidity, mortality and healthcare cost 
relates to exacerbations.
These aforementioned data make prompt 
intervention to reduce the burden of COPD 
imperative, particularly mitigation of exac-
erbations. Studies have shown that COPD 
outcomes can be improved with various 
interventions including smoking cessation, 
pulmonary rehabilitation, influenza vaccine, 
pharmacotherapy and lung volume reduc-
tion.1–6 Patients susceptible to frequent exac-
erbations experience poorer outcomes and 
excess healthcare cost.7–9
For exacerbations that do occur, facilitating 
prompt access to therapy is important since 
there is some evidence to suggest that early 
therapy may be associated with more rapid 
resolution of symptoms and reduced risk 
of hospitalisation10—though this has never 
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been documented as a primary outcome in a rigorous 
randomised controlled study.
Supporting people living with COPD to maintain respi-
ratory health, and to access care at the time of exacerba-
tion remains a challenge. One approach that may facilitate 
the management of COPD is telehealth.11 12 Telehealth 
has been defined by the Telehealth Quality Group as ‘the 
means by which technologies and related services concerned with 
health and well-being are accessed by people or provided for them 
irrespective of their location.’13 Telehealth for COPD could 
be used for various purposes such as symptom moni-
toring, exacerbation detection, reinforcement of educa-
tion and support for rehabilitation.14–16 While some 
studies have reported that the use of telehealth in COPD 
may improve outcomes,17 the evidence for cost-effective-
ness remains limited.15 18 Telehealth cost per quality-ad-
justed life years (QALY) at £92 000/QALY on the ‘COPD 
value pyramid’ was the highest cost compared with other 
interventions, such as influenza vaccination (£1000/
QALY) and pulmonary rehabilitation (£2000–£8000/
QALY).19 According to a systematic review conducted by 
Polisena et al in 2010, examining four observational and 
six randomised studies, the use of telehealth with COPD 
appeared to be associated with a reduction of hospital 
admission rate, length of stay and emergency depart-
ment visits (p<0.05).20 More recent studies including 
a well-conducted randomised trial by Pinnock did not 
show improvement in outcomes including risk of hospi-
talisation and quality of life.21 Moreover, inappropriate 
use of telehealth could adversely affect care provided. In 
particular, an effective telehealth programme requires 
accurate and reliable setting of alarm limits to avoid 
unnecessary action or cost.
It is not clear how widespread the use of telehealth for 
COPD is in the National Health Service (NHS) England 
and Wales, or for what purposes it is being used. We 
set out to explore this. We hypothesised that different 
services would be using different methods to set tele-
health alarms, with no clear guideline on how to person-
alise the alarm limits for each patient.
Method
A cross-sectional survey consisting of 14 questions (see 
online supplementary appendix 1) was sent to COPD 
community services in England and Wales. The organisa-
tions were those taking part in the Pulmonary Rehabilita-
tion (PR) arm of the National COPD Audit Programme 
in September 2017. The organisations providing PR are 
frequently community health providers, and therefore 
those most likely to be using telehealth programmes. 
The survey was administered via SurveyMonkey in 2017. 
The questions were developed by the authors and tested 
for validity with local practitioners before being elec-
tronically distributed on email to the COPD community 
organisations. We assessed content and face validity. First, 
the first author developed the questions from his health-
care professional background and experience. Next, the 
content was evaluated by two healthcare professional 
experts including one of the authors (JRH). Amend-
ments to the questions were made in accordance with 
their comments and feedback. The face validity was 
checked by distributing the survey to a variety of health-
care professionals (doctors, nurses and physiotherapists). 
They provided feedback about the ease of completing 
the survey and whether it was measuring what we had 
intended to measure. The final version of the survey was 
then confirmed by all authors.
A cover statement explained the purpose of this survey. 
We additionally advertised availability of the survey by 
circulating the weblink electronically via email, Twitter 
and LinkedIn. Under the Research Governance Frame-
work (2005), and Health Research Authority (HRA) 
review, this study was not considered as ‘research’ as this 
was a voluntary survey of healthcare professionals; there-
fore, no ethics, HRA, or Research and Development 
approvals were required.
Questions were designed to cover five different aspects 
of telehealth in COPD: purpose of use, equipment type, 
clinician perceptions, variables monitored and personal-
isation of alarm limits. Participants were asked to select 
which type of equipment was used in their service: 
(A) smartphone/tablet apps, (B) monitoring station 
(non-portable telehealth equipment fixed in the patient’s 
home), (C) fixed telephone, (D) video phone, and (E) 
other (please specify). For variables monitored, partic-
ipants were asked to select all the variables that were 
monitored in their programme. We asked about heart 
rate, oxygen saturation, respiratory rate, blood pressure, 
temperature, peak flow, hours of continuous positive 
airway pressure use, hours of non-invasive ventilation 
(NIV) use, step count, physical activity, metabolic equiv-
alent data, sleep quality, phlegm, cough, breathlessness, 
wheeze and use of rescue medication, and participants 
had the option to add any variables that were not listed in 
free text. For any variables being used, participants were 
then asked how the alarm limit for each variable was set 
from a drop-down list (arbitrary, international guide-
lines, national guidelines, personalised to the patient, 
don’t know or not applicable). Participants who indi-
cated that the alarm limit was personalised were asked 
how this was done. Participants did not have to answer all 
the questions.
With regard to questions on clinician perception, 
responses were graded on a Likert scale between 1 (not 
at all) and 10 (very much so). Statistical Package for 
the Social Sciences (SPSS) V.24 was used to analyse the 
collected responses. P≤0.05 was accepted as the level of 
significance.
results
Two hundred and thirty organisations were invited to 
take part in this survey. Sixty-five participants completed 
the survey from 52 different organisations (50 in England 
and two in Wales). Twenty-four (46%) of organisations 
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Figure 1 Variables monitored by telehealth providers.
had used telehealth for COPD, and currently, 16 (31%) 
still provided telehealth services to patients with COPD. 
Of the respondents, 36/65 (55%) were physiotherapists, 
23% nurses, 12% miscellaneous, 8% doctors and 2% 
physiologists.
Perception
Fifty-two of 65 respondents completed the question about 
the usefulness of telehealth, where 0 represented ‘not at 
all’ and 10 represented ‘very much so’. The median and 
IQR score was 53–7 out of 10 on the Likert scale. In respond-
ents who had used (n=28, median (IQR) 6 (3–7)) vs had 
not used (n=24, median (IQR) 5 (2–7)) telehealth, there 
was a difference in score of 1.0 which was not statistically 
significant (p=0.38). Participants thought that telehealth 
was useful in diverse aspects of COPD care, for example: 
‘stops unnecessary visits’, ‘clients know they can contact 
us rather than waiting to see the GP or going to hospital’, 
‘symptom monitoring/alerting to exacerbations’, ‘we 
don't use it, but I suppose education/information’.
Purpose and equipment
Of those who still used telehealth, 88% used it for base-
line monitoring, 82% for early detection of exacerba-
tions, 41% for monitoring recovery from an exacerba-
tion and 12% to assist patient adherence to management 
plan, which was reported by participants as exercise 
adherence, inhaler adherence and monitoring domi-
ciliary NIV. Differential responses here may reflect the 
workload prioritisation of community teams. Some 
respondents used it for more than one indication. The 
equipment used (hardware) was a dedicated monitoring 
station (non-portable telehealth equipment that is fixed 
in the patient’s home) in 50%, a smartphone/tablet app 
in 46% and a fixed telephone in 36%.
The variables being monitored in more than 50% of 
services are illustrated in figure 1. This was most commonly 
oxygen saturation, heart rate and breathlessness.
Alarm limits
Table 1 shows how each respondent set the alarm limits 
for each variable they monitored. The majority selected 
either ‘National guidelines’ (although no such guidance 
exists) or ‘personalised’. For personalisation techniques, 
the participants’ answers could be categorised into four 
methods: observation taken at the time of set-up assess-
ment, historical trends, calculation of a stable baseline, or 
a combination of set-up assessment and historical trend.
With regard to perceived sensitivity to detect exac-
erbation, 56% of 18 respondents thought their alarm 
technique was sensitive enough to identify exacerbation 
events. With regard to the efficiency of personalising 
alarm limits over arbitrary, the median (IQR) score on 
the Likert scale was 54–8 in 17 participants, suggesting that 
there was no consensus on the utility of this approach.
Finally, we asked about the perceived proportion of 
‘false alarms’. These data are illustrated in figure 2. The 
majority of participants thought that at least 40% of 
alarms were false.
dIscussIon
We have conducted a national survey to explore the use 
of teleheath in COPD across England and Wales, and to 
summarise the techniques used by healthcare providers to 
personalise alarm limits for patients with COPD enrolled 
in telehealth programmes. Our key findings are: Of the 52 
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Table 1 Participants’ description of how alarm limits were set for each variable. Variables are ordered by frequency of use 
(see figure 1)
Variables
Arbitrary/what 
feels right
Local 
guideline
National 
guideline
Personalised 
(based on 
data from that 
patient) Not applicable Total
Oxygen saturation 0%
0
13%
2
27%
4
53%
8
7%
1
15
Heart rate 0%
1
17%
2
8%
1
67%
8
8%
1
13
Breathlessness 8%
1
17%
2
17%
2
42%
5
17%
2
12
Cough symptoms 8%
1
8%
1
17%
2
42%
5
25%
3
12
Phlegm symptoms 9%
1
18%
2
27%
3
18%
2
27%
3
11
Temperature 0%
0
27%
3
46%
5
18%
2
9%
1
11
Blood pressure 0%
0
18%
2
18%
2
55%
6
9%
1
11
Wheeze 13%
1
13%
1
25%
2
25%
2
25%
2
8
Physical activity 14%
1
0%
0
0%
0
43%
3
43%
3
7
Use of medication 0%
0
14%
1
29%
2
29%
2
29%
2
7
Hours of NIV use 0%
0
20%
1
0%
0
20%
1
60%
3
5
Sleep quality 0%
0
0%
0
0%
0
75%
3
25%
1
4
Step count 25%
1
0%
0
0%
0
25%
1
50%
2
4
Peak flow 0%
0
0%
0
0%
0
33%
1
67%
2
3
NIV, non-invasive ventilation.
organisations that responded, 16 (31%) currently use tele-
health, 28/52 (54%) practitioners thought telehealth was 
useful in COPD (despite a high proportion of false alarms, 
and this did not vary by experience of use), telehealth is 
most commonly delivered from a fixed monitoring station 
(non-portable telehealth equipment that is fixed in the 
patient’s home), and the most common variables moni-
tored are oxygen saturation, heart rate and breathlessness 
score. Alarm limits for these variables were most commonly 
said to be personalised, using a variety of non-standardised 
techniques, or set using guidelines, which to the best of our 
knowledge do not exist.
It was not clear how widespread the use of telehealth 
for COPD was in NHS clinical practice. While around 
one-third of organisations currently used telehealth, there 
is not a single record of all organisations providing commu-
nity COPD care, and therefore we cannot comment on the 
overall prevalence of use, and telehealth may in addition 
be provided by primary and secondary care organisations.
The usefulness of telehealth in COPD remains contro-
versial. Based on this survey, most participants thought that 
telehealth was useful for managing patients with COPD, 
despite an absence of robust clinical trial evidence and 
despite responses in this survey suggesting a high propor-
tion of false alarms. This suggests that further qualita-
tive work is required to understand why some clinicians’ 
perceptions do not match the available evidence. Some 
studies have shown positive results when telehealth is used 
in patients with COPD, for example, a reduction in emer-
gency department visits, need for NIV, hospital admissions 
and hospital length of stay,14 which will indirectly affect the 
cost of patient with COPD on healthcare. Other studies 
have not been positive. Ringbaek et al noted no signif-
icant benefit of telehealth on hospital admissions due to 
exacerbation or emergency department visits22 and the 
randomised trial by Pinnock did not improve admission 
rates of quality of life.21
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Figure 2 Perception of false alarms triggered from telehealth system.
The majority of participants who used telehealth in 
COPD used it for baseline monitoring and early detection 
of exacerbation. The variables monitored by providers 
included symptoms and physiological parameters. Heart 
rate, oxygen saturation and breathlessness were the most 
common variables monitored, each in >50% of services. In 
a pilot study in 2010, we demonstrated that daily physio-
logical monitoring has the potential to provide early detec-
tion of COPD exacerbations.23 Other more recent studies 
have also shown the possibility of predicting COPD exac-
erbation via close monitoring of patients’ symptoms and 
physiological variables.24–26 However, in a recent systematic 
review, we concluded that there is currently insufficient 
information on how physiological parameters vary prior 
to exacerbation to support routine domiciliary monitoring 
solely for the prediction of exacerbations.27 Moreover, the 
National Institute for Health and Care Excellence 2018 
guideline has recommended not offering routine tele-
health (physiological monitoring) for patients with stable 
COPD, as evidence remains controversial.28 Regarding 
symptoms, in 2000 Seemungal et al noted a significant 
increase in respiratory symptoms (dyspnoea, cough and 
sore throat) prior to exacerbation with up to 64% of partic-
ipants reporting increased dyspnoea on the day of onset 
of an exacerbation.29 Thus, monitoring breathlessness in a 
telehealth programme might be valuable, but again there 
remains insufficient evidence to be able to recommend this 
routinely.
One major challenge with the use of telehealth is the 
question of how best to set alarm limits. Too sensitive and 
there will be excess false alarms, not sensitive enough and 
exacerbations will be missed. The majority of participants 
(59%) in this survey thought that >40% of alarms received 
from telehealth systems were false, which is perhaps why 
some participants did not agree that personalising alarm 
limits made telehealth services more efficient, as a high 
number of false alarms could lead to alarm fatigue, unnec-
essary actions and unnecessary clinical workload. This 
is consistent with published evidence which has shown 
that more than 72% of alarms are not clinically related.30 
Triggered alarms could be due to technical issues, sensor 
malposition, changes in therapy and poor clinical judge-
ment. Even though there is no robust evidence to either 
agree or disagree with some of the techniques of how alarm 
limits were personalised, techniques were similar to those 
reported in our systematic review.27 This survey emphasises 
the need for testing, optimising and establishing a protocol 
for personalisation of alarm limits. Many participants 
reported using national guidance to personalise limits, 
even though no such guidance exists. We have previously 
reported our experience of setting alarm limits based on 
calculating baseline variation in monitored variables, and 
using Z scores to distinguish normal from abnormal varia-
tion.23 Further work is required to understand how to best 
establish patients on telehealth programmes.
strengths and limitations
Our survey has some limitations. We cannot be sure we 
reached a representative sample of all organisations 
providing telehealth. The survey was distributed elec-
tronically and no reminder was sent to fill and submit the 
survey, which may have contributed to the low response 
rate. Responders who completed this survey were from a 
wide range of providers, such as doctors, nurses and physi-
otherapists, but we did not set out to survey the opinions of 
healthcare commissioners. Findings from this study should 
be interpreted with a caution, as some questions were 
answered from a smaller number of participants. Further-
more, the responders to this survey in 52/230 organisa-
tions could be biased towards either a positive or negative 
view of telehealth in COPD depending on their previous 
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experience, and we have no way to assess this. The strength 
of our survey is that, to our knowledge, there is no previous 
survey assessing the use and purpose of telehealth for 
COPD in the NHS, or the techniques of personalisation of 
alarm limits. Further studies could consider, in particular, 
how telehealth has changed practice, and how patients are 
selected for telehealth programmes.
conclusIon
Around one-third of responding community COPD 
services are using telehealth, believing it to be somewhat 
effective without robust evidence, monitoring a variety of 
variables and using a variety of hardware and techniques to 
set alarm limits with resultant high false alarm frequency. 
This potentially increases clinical workload and actions; 
therefore, further robust research is needed to evaluate the 
utility of telehealth, and specifically the efficacy of person-
alising alarm limits and the validity of this approach in clin-
ical practice prior to wider implementation in the NHS UK 
and more widely.
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